- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02841150
Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules
March 28, 2018 updated by: Janssen Research & Development, LLC
A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 560-mg Tablet Compared to the Four IMBRUVICA 140 mg Capsules
The purpose of this study is to demonstrate the bioequivalence (BE) of a new formulation of ibrutinib to the marketed Imbruvica formulation in healthy adults under fasted conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study, before any study related procedures take place
- Willing and able to adhere to the prohibitions and restrictions specified in the protocol
- If a woman, must be of non-childbearing potential, defined as either: a) Postmenopausal: A postmenopausal state is defined as no menses for at least 12 months without an alternative medical cause and a serum follicle stimulating hormone (FSH) level in the postmenopausal range (greater than [>]40 international units per liter [IU/L] or milliinternational units per milliliter [mIU/mL]). b) Permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures (without reversal operation), bilateral oophorectomy, and/or transcervical sterilization
- If a woman, must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and on Day -1 of each treatment period
- Non-smoker for at least 2 months prior to screening
Exclusion Criteria:
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen/paracetamol, topical therapies, and hormone replacement therapy within 14 days before the first dose of the study drug is scheduled
- History of clinically significant allergies, especially known hypersensitivity or intolerance to sulfonamide or beta-lactam antibiotics
- Known allergy to the study drug or any of the excipients of the formulation
- Unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
- Positive test for human immunodeficiency virus type 1 (HIV-1) or HIV-2 antibodies at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Sequence 1
Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
|
IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
Other Names:
Ibrutinib (test treatment), 1*560 mg, tablet.
|
Experimental: Treatment Sequence 2
Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
|
IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
Other Names:
Ibrutinib (test treatment), 1*560 mg, tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The Cmax is the maximum observed plasma concentration.
|
Day 1 (Pre-dose) up to Day 3
|
Time to reach maximum concentration (tmax) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Day 1 (Pre-dose) up to Day 3
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
|
Day 1 (Pre-dose) up to Day 3
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Day 1 (Pre-dose) up to Day 3
|
Elimination Rate Constant (Lambda[z]) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.
|
Day 1 (Pre-dose) up to Day 3
|
Terminal Half-Life (t[1/2]) of Ibrutinib
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Day 1 (Pre-dose) up to Day 3
|
Maximum Plasma Concentration (Cmax) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The Cmax is the maximum observed plasma concentration.
|
Day 1 (Pre-dose) up to Day 3
|
Time to reach maximum concentration (tmax) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Day 1 (Pre-dose) up to Day 3
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
|
Day 1 (Pre-dose) up to Day 3
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Day 1 (Pre-dose) up to Day 3
|
Elimination Rate Constant (Lambda[z]) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
Lambda(z) is first-order elimination rate constant associated with the terminal portion of the curve, determined as the negative slope of the terminal log-linear phase of the drug concentration-time curve.
|
Day 1 (Pre-dose) up to Day 3
|
Terminal Half-Life (t[1/2]) of IMBRUVICA
Time Frame: Day 1 (Pre-dose) up to Day 3
|
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Day 1 (Pre-dose) up to Day 3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events and serious adverse events as a measure of safety and tolerability
Time Frame: Baseline up to 14 days after last dose of study drug (Day 17)
|
Baseline up to 14 days after last dose of study drug (Day 17)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
June 15, 2016
First Submitted That Met QC Criteria
July 19, 2016
First Posted (Estimate)
July 22, 2016
Study Record Updates
Last Update Posted (Actual)
March 29, 2018
Last Update Submitted That Met QC Criteria
March 28, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- CR108171
- 54179060CLL1021 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on IMBRUVICA (Treatment A)
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
Janssen Research & Development, LLCCompleted
-
PfizerCompleted
-
Hospices Civils de LyonCompletedAcquired Visual Field DefectsFrance
-
PfizerCompletedHealthyUnited States
-
PfizerCompleted
-
PfizerCompleted
-
AstraZenecaParexelCompletedCoronary Artery DiseaseUnited Kingdom
-
Novartis PharmaceuticalsCompleted